PCRX Pacira BioSciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1396814 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.7%
TTM net income YoY76.0%
TTM EPS YoY97.9%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR75.5%
Margins
Gross margin78.7%
Operating margin4.8%
Net margin5.1%
FCF margin22.7%
EBITDA margin12.4%
Returns
ROE5.2%
ROA3.0%
ROIC (approx.)4.2%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets40.8%
Debt / equity0.41x
Current ratio4.68x
Interest coverage2.54x
Cash quality & payout
Operating cash flow / net income4.69x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $176.65M | $192.40M | $177.38M | $196.87M | $179.52M | $181.10M | $168.92M | $187.25M |
| Cost of revenue | $37.23M | $44.16M | $36.41M | $40.30M | $34.28M | $40.87M | $34.31M | $39.89M |
| Gross profit | $139.42M | $148.24M | $140.96M | $156.57M | $145.24M | $140.23M | $134.62M | $147.37M |
| R&D expense | $26.68M | $30.24M | $28.07M | $37.45M | $25.97M | $28.20M | $25.34M | $23.90M |
| SG&A expense | $83.84M | $91.81M | $93.94M | $101.61M | $91.80M | $88.58M | $86.78M | $79.61M |
| Operating income | $22.27M | $4.27M | $6.90M | $2.34M | $6.36M | $8.50M | $1.99M | $24.70M |
| Interest expense | $2.88M | $3.62M | $3.70M | $3.89M | $4.28M | $4.70M | $4.58M | $4.68M |
| Pretax income | $28.81M | $2.56M | $5.00M | $571,000 | $9.52M | -$1.93M | $8.71M | $25.53M |
| Income tax | $293,000 | -$2.10M | $2.08M | -$1.07M | $4.09M | $2.92M | $3.89M | $9.48M |
| Net income | $28.52M | $4.65M | $2.92M | $1.64M | $5.43M | -$4.85M | $4.81M | $16.04M |
| EBITDA | $29.17M | $11.27M | $28.23M | $23.68M | $13.26M | $21.50M | $23.16M | $45.95M |
| EPS (basic) | 0.72 | 0.12 | 0.07 | — | 0.12 | -0.11 | 0.10 | — |
| EPS (diluted) | 0.70 | 0.12 | 0.07 | — | 0.12 | -0.11 | 0.10 | — |
| Weighted avg. shares (diluted) | 40.83M | 40.30M | 40.91M | — | 44.46M | 45.46M | 46.53M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $246.96M | $205.88M | $144.31M | $158.54M | $147.59M | $300.48M | $283.61M | $276.77M |
| Short-term investments | $48.62M | $45.16M | $57.87M | $79.88M | $98.75M | $145.38M | $210.02M | $207.84M |
| Receivables | $122.89M | $132.42M | $125.64M | $124.07M | $115.27M | $114.37M | $104.75M | $113.30M |
| Inventory | $129.49M | $134.57M | $150.37M | $152.86M | $157.68M | $148.16M | $133.75M | $125.28M |
| Current assets | $590.23M | $615.22M | $514.96M | $547.97M | $562.75M | $745.61M | $759.96M | $745.13M |
| PP&E, net | $129.18M | $130.28M | $136.28M | $140.69M | $147.39M | $155.18M | $164.45M | $167.17M |
| Goodwill | $19.54M | $19.64M | $19.77M | $20.21M | $20.32M | $20.30M | $21.52M | $0 |
| Intangibles | $273.00M | $285.48M | $353.23M | $368.10M | $382.40M | $422.56M | $434.97M | $425.97M |
| Total assets | $1.20B | $1.24B | $1.21B | $1.26B | $1.30B | $1.54B | $1.59B | $1.55B |
| Current liabilities | $126.10M | $122.01M | $108.79M | $120.59M | $107.08M | $313.16M | $314.73M | $309.92M |
| Short-term debt | — | — | — | $0 | $0 | — | — | $201.78M |
| Long-term debt | $293.59M | $363.12M | $367.66M | $372.19M | $376.72M | $580.49M | $583.38M | $383.55M |
| Total debt | $293.59M | $363.12M | $367.66M | $372.19M | $376.72M | $580.49M | $583.38M | $585.32M |
| Total liabilities | $490.32M | $572.00M | $554.64M | $571.81M | $570.36M | $779.50M | $788.13M | $775.17M |
| Shareholders' equity | $712.32M | $671.98M | $653.89M | $693.11M | $727.21M | $757.77M | $798.54M | $778.35M |
| Net debt | $46.63M | $157.25M | $223.35M | $213.64M | $229.13M | $280.01M | $299.77M | $308.55M |
| Shares outstanding | 39.90M | 39.82M | 39.31M | 41.12M | 42.97M | 44.90M | 46.28M | 46.24M |
| Cash flow statement | ||||||||
| Operating cash flow | $50.07M | $57.46M | $25.68M | $43.69M | $60.83M | $12.01M | $35.46M | $33.13M |
| Capital expenditure | $3.62M | $1.34M | $2.72M | $218,000 | $3.87M | $2.70M | $8.55M | $2.12M |
| Free cash flow | $46.45M | $56.12M | $22.96M | $43.47M | $56.96M | $9.31M | $26.91M | $31.01M |
| Investing cash flow | $60.81M | $11.76M | $19.44M | $19.33M | $43.61M | $62.16M | -$25.63M | -$368,000 |
| Financing cash flow | -$69.77M | -$7.65M | -$59.40M | -$51.65M | -$257.48M | -$57.51M | -$2.99M | -$1.96M |
| Depreciation & amortization | $6.90M | $7.00M | $21.33M | $21.34M | $6.90M | $13.00M | $21.17M | $21.24M |
| Stock-based compensation | $11.82M | $14.96M | $13.54M | $13.50M | $13.98M | $15.47M | $14.55M | $12.27M |
| Share buybacks | $0 | $0 | $50.05M | $48.25M | $50.04M | $50.04M | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.